Treatment of Joints pain with Unani medicine Habbe Gule Aak and Roghane Hina
- Conditions
- Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
- Registration Number
- CTRI/2024/07/070679
- Lead Sponsor
- Central Council for Research in Unani Medicine CCRUM New Delhi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients of either sex in the age group of 18-60
2. Patients fulfilling the ACR criteria for rheumatoid arthritis
1. Patients having Gout, or complicated rheumatoid arthritis associated with deformity.
2. Abnormality in any investigation done at baseline (SGOT, SGPT and ALP, Sr Creatinine, B. Urea would be considered abnormal if raised more than 2 and half times the normal value), also Patients with GFR less than 60 will be exclude from the study.
3. Severe cases of RA (Stage III & IV) & diagnosed cases of ankylosing spondylosis will be excluded from the study.
4. Patient with High grade fever will be excluded from the study
5. Disorders requiring long term treatment
6. Cases with systemic manifestation of Rheumatoid arthritis
7. Patient is on treatment for any illness related to Endocrine & metabolic disorders
8. Drug addicts (Alcohol, drugs)
9. Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of the study drug in the treatment of Waja ul Mafasil (Rheumatoid Arthritis) will be assessed on the basis of Reduction of the 2010 ACR-EULAR Rheumatoid Arthritis Classification Criteria scores from baseline to the end visit of the Study. <br/ ><br>Timepoint: On each fortnight for 12 weeks
- Secondary Outcome Measures
Name Time Method Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and 12 weeks